Getting a drug to market takes years. A lot of that time disappears into broken systems — outdated data pipelines, compliance paperwork done manually, siloed teams that can’t share data. Regulators are tightening requirements.
AI is changing how trials get designed. And somewhere in the middle, IT vendors are trying to keep up. This piece looks at six companies actually worth paying attention to in 2026.
The Companies
1. DXC Technology (USA/Global)
DXC isn’t a startup pitching a demo. They’ve been delivering IT infrastructure for pharma and biotech clients for years, and the scope of what they cover is genuinely broad.
On the clinical side, they handle data integration across EDC systems, wearables, and patient-reported outcomes — all the messy inputs that end up needing to talk to each other before a submission.
On the regulatory side, they work with eCTD-structured content management. Pharmacovigilance teams use their tools to process adverse event cases without drowning in manual work.
What’s notable in 2026: their AI capabilities plug into existing SAP and Veeva environments rather than requiring companies to start over.
For a mid-size biotech with an existing stack, that’s the difference between a six-month rollout and a two-year nightmare.
More details at: https://dxc.com/industries/life-sciences-solutions
2. Inato (France)
Inato solves a specific, painful problem: finding qualified investigative sites for clinical trials. Sponsors waste months doing this manually. Inato’s platform matches sponsors to sites using historical performance data — real numbers on how sites have run previous trials.
What the platform includes:
- Site identification with performance-based scoring
- Patient population overlays for feasibility analysis
- Hybrid and decentralized trial support
Roche and Sanofi have both run trials through it. As decentralized studies become standard, platforms like this stop being “nice to have.”
3. Arriello (Ireland/Czech Republic)
Arriello does one thing and does it well: regulatory compliance technology. Their RIMS product, Archipelago, handles product registration tracking across 180+ markets, submission planning, variation management, and integration with EMA SPOR and XEVMPD systems.
Why they matter:
- Deep EU regulatory knowledge — not generic compliance
- Useful for smaller pharma without a dedicated regulatory IT team
- No sprawling product portfolio, just focused execution
4. Veeva Systems (USA)
Veeva is the de facto infrastructure layer for commercial pharma. Their Vault platform runs eTMF, RIM, QMS, and commercial content management at most major pharma companies. FDA 21 CFR Part 11 compliance is built in. The CRM handles field medical and sales teams with HCP data already integrated.
The honest critique: once you’re on Vault, migration is genuinely painful. Which also means it’s a product people actually use and depend on — not shelf software. Their newer Veeva Data Cloud push moves them into data-as-a-service territory.
5. Saama Technologies (USA/India)
Saama built their Life Science Analytics Cloud specifically for R&D teams — not general analytics repackaged for pharma.
Clinical operations, biostatistics, and data management teams use it to clean trial data faster, spot anomalies early, and run study dashboards across Medidata Rave and Oracle Clinical integrations.
They were involved in COVID-era trial acceleration work — which gave their platform real stress-testing most vendors never experienced.
6. OpenText (Canada)
OpenText isn’t life-sciences-only, but their Extended ECM product maps directly onto pharma manufacturing needs.
Batch records, SOPs, CAPA workflows, change control — all managed with GxP-compliant audit trails and electronic signatures. Sits on top of SAP environments, which is where most large manufacturers already live.
Before Signing Anything
A few things worth checking with any vendor on this list:
- Regulatory specificity — can they name the ICH guidelines or eCTD modules relevant to your submission? Generic answers mean generic solutions
- Real integrations — which EDC or CTMS systems have they connected in production, not just in pitch decks
- EU data residency — post-Schrems II, this isn’t optional paperwork
- AI explainability — FDA and EMA are watching how AI decisions get documented in regulated workflows
FAQs
What falls under “life sciences IT”?
Clinical trial systems, pharmacovigilance platforms, regulatory submission tools, QMS, ERP, and analytics — anything touching R&D, manufacturing, or commercial ops in pharma and biotech.
Do smaller companies need specialized vendors?
Yes. A biotech filing its first IND has no team to build GxP infrastructure from scratch. Purpose-built vendors save months of validation work.
Is cloud viable in regulated environments?
Yes, if validated and aligned to FDA 21 CFR Part 11 and EU Annex 11. Vendor qualification documentation is the key question.
What is AI actually doing here?
Speed and anomaly detection — adverse event processing, clinical data quality flags, feasibility modeling. Regulatory sign-off stays with humans.
With many years of professional experience within transnational corporations in different industries, Richard Jaimes has had the opportunity to lead people and organizations, investigate future topics, create strategies and innovations, consult senior management and translate insights into business advantages. Richard is also a long time senior consultant with Quantumrun Foresight.
